Mabion SA

  • Mabion Headquarter
About Mabion SA

Mabion is a fully integrated CDMO offering a wide array of services associated with the development and manufacturing of protein-based biotherapeutics, including monoclonal antibodies and vaccine antigens. With 16 years' experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process scale-up, large-scale manufacturing and quality control down to sterile fill-finish, packaging and serialization, bioanalytics and regulatory support.

Certifications
  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Clinical Research
Contract Manufacturer
Contract Research Organisation
End-product distributor (Wholesale)
Intermediates Manufacturer
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Mabion SA (1)

  • MabionCD20

    Product MabionCD20

    This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.

Mabion SA Resources (2)

  • News Mabion signs contract to purchase new bioreactors, diversifies technology, and opens to new customers

    On July 11th, 2023, Mabion concluded an agreement with Global Life Sciences Solutions Polands Sp. z o.o., a Cytiva group company for the purchase of a set of Xcellerex XDR bioreactors with conventional mixing technology. The contract is valued at EUR 3.2 million.The vendor will manufacture and install a set of bioreactors in Mabion's facility in Konstantynów Łódzki, Poland, delivery of which is scheduled for Q3 2023, followed by installation, commissioning, qualification testing and acceptance of the equipment. The Xcellerex XDR bioreactor suite is based on technology using a conventional mixing system, as opposed to Mabion's current orbital shaking technology, which will allow the Company to achieve technological diversification, as outlined in the 2023-2027 Strategy in earlier this year.
  • Brochure Mabion - Your Biologics CDMO

    A presentation including a demonstration of Mabion's capabilities as a biologics CDMO.